According to a recent Impact Report from the Tufts Center for the Study of Drug Development, 21% of active clinical trials improve trial success rates and cut operating costs by designing trials with simple adaptive elements like sample size re-estimation and opportunities for early stopping.
Cytel Senior Biostatistician Zoran Antonjevic, who also chairs the DIA’s Adaptive Design Scientific Working Group (ADSWG), says the CSDD's findings come very close to the numbers reported by the ADSWG. The ADSWG recently updated its published findings in a Therapeutic Innovation & Regulatory Science article entitled, ‘Adaptive Design: Results of 2012 Survey on Perception and Use.’ The Survey team, led by Cytel statistician and Senior Director Caroline Morgan, used a variety of source material to report on adaptive designs in clinical trials between 1996 and 2012.
How can you determine whether your next trial will benefit more from a simple adaptive design or a complex trial? One place to start is by looking at our 10 step guidance 'To Adapt or not to Adapt? 10 Simple Steps to Determining whether your Next Trial Should be Adaptive.'
Related Items of Interest
Morgan, Caroline Claire, et al. "Adaptive Design Results of 2012 Survey on Perception and Use." Therapeutic Innovation & Regulatory Science (2014): 2168479014522468
Nayak, R. and Bolognese, J. Adaptive Clinical Trials. Cytel Whitepaper.
Cytel Blog, To Adapt or not to Adapt? 10 Simple Steps to Determining whether your Next Trial Should be Adaptive.
